Search results for: Maria Lowe
Filter search results
OHE at iHEA 2017: Presentations
8 August 2017
…on rates of return from investments in developing orphan drugs. He suggested that the price for an orphan drug should not sustain rates of return greater/lower than the industry average,…
New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
11 August 2017
…cause of lower quality may be addressed through P4P, whilst; Incomplete information may be best addressed through report cards; Coordination of care at the system, or national, level is essential…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive…
Cancer Survivorship Burden
6 March 2018
…be lower among cancer survivors who were diagnosed in childhood. Indirect costs are more difficult to estimate than the direct costs incurred by the health care system, particularly due to issues…
Minimal Access Surgery – Why Don’t We Do More?
20 March 2018
…growing evidence base supporting the clinical and cost-effectiveness of MAS for three specific procedures: hysterectomy, ventral/incisional hernia repair, and lower anterior resection. However, despite the benefits, uptake of MAS is…
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
…price for the three countries Hill et al. (2018) analyse. In India, 47% of medicines have observed prices that are 50% lower than the projected efficient price. In contrast, 78%…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…medicines are not used by some patients, countries, or systems. Quantities sold are lower than the quantity that would maximise social welfare, given the existence of the product. Our…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
…treatment, and for some observations, the drug used in the control arm may also be changed. There is thus a trade-off between the lower random error from increasing the number…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
…competition, which in turn has a lowering effect on the level of prices. Payers are also concerned about the complexity of MIP and the resources (e.g. staff from the department…